Annexon, Inc.
1400 Sierra Point Parkway, Bldg C, Suite 200
Brisbane, California 94005
November 14, 2022
Via EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Annexon, Inc. |
Registration Statement on Form S-3
Filed November 4, 2022
Registration No. 333-268181
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Annexon, Inc. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on November 16, 2022, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Please contact Kathleen M. Wells of Latham & Watkins LLP, counsel to the Company, at (650) 463-2677, or in her absence, Richard Kim of Latham & Watkins LLP at (650) 470-4980, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.
Thank you for your assistance in this matter.
* * * *
| Sincerely, | ||
| Annexon, Inc. | ||
| By: | /s/ Jennifer Lew | |
| Jennifer Lew | ||
| Chief Financial Officer and Secretary | ||
| cc: | Douglas Love, Esq., Annexon, Inc. |
Kathleen M. Wells, Latham & Watkins LLP
Brian J. Cuneo, Latham & Watkins LLP
Richard Kim, Latham & Watkins LLP